Deutsche Bank Has Buy on Fluidigm
Deutsche Bank is out with a research report on Fluidigm (NASDAQ: FLDM) and it has a Buy rating and a $18 price target on shares.
In a note to clients, Deutsche Bank writes, "Key takeaways from CC: 1) In-line revenues, with BioMark / Access Array demand driven by single cell analysis / next gen sample prep applications; 2) Installed base of instruments at 440, with 60% of sales in the Q driven by analytical instruments (remaining by sample prep); 3) Raised FY11 product revenue growth guidance to a range of 31%-33% from prior 27%-30%. We believe that the company's innovative technology positions it well for future growth, so reiterate our Buy rating. PT goes to $18.00 (was $21.00 prior) on peer multiple contraction."
Shares of FLDM are off 37 cents to $13.28.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.